# Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

> **NCT04021108** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Weill Medical College of Cornell University** · enrollment: 80 (actual)

## Conditions studied

- Gastroesophageal Adenocarcinoma

## Interventions

- **DRUG:** Nivolumab 240 MG

## Key facts

- **NCT ID:** NCT04021108
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-22
- **Primary completion:** 2025-06-11
- **Final completion:** 2026-06
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04021108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04021108, "Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04021108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*